Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co (NYSE:LLY) and ...
In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs ...
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...
On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...
Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox. Alphabet-owned Isomorphic Labs is ramping up its operations by poaching pharmaceutical talent and opening ...
Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback